The earnings call highlighted strong financial performance and product growth across key areas, supported by positive pipeline developments and an upgraded full-year guidance. However, challenges were noted in the competitive landscape and specific market pressures, such as in China and the U.S. with potential generic competition for Entresto.

Company Guidance

During the Novartis Q2 2025 earnings call, the company reported significant financial growth, with a notable 11% increase in sales and a 21% rise in core operating income, both in constant currency. The core margin expanded by 340 basis points to 42.2%, and core EPS grew by 24% to $2.42. Free cash flow increased by 37% to $6.3 billion. Novartis upgraded its full-year 2025 guidance, projecting core operating income growth in the low teens. Key growth drivers included a diverse portfolio of products, such as Kisqali, which grew 64% in the quarter, and Kesimpta, with a 33% increase. Additionally, Novartis announced a new up to $10 billion share buyback program, reflecting its robust financial health and commitment to balanced capital allocation.

Strong Sales and Core Operating Income Growth

Novartis reported double-digit sales growth of 11% and a 21% increase in core operating income in constant currency for Q2 2025.

Upgrade in Full-Year Bottom Line Guidance

The company has upgraded its full-year 2025 bottom line guidance, reflecting strong business momentum and ongoing productivity improvements.

Key Product Performance

Kisqali grew 64% with U.S. growth up 100% in Q2. Kesimpta grew 33%, and Leqvio grew 61%. Scemblix showed 79% growth, and Pluvicto returned to 30% growth.

New Share Buyback Program

Novartis initiated a new up to $10 billion share buyback program targeted for completion by the end of 2027.

Positive Pipeline Developments

Positive Phase III results for Pluvicto in metastatic hormone-sensitive prostate cancer and remibrutinib in food allergy.

Innovative Milestones

Progress in pipeline with initiatives such as Phase I/II data on YTB for immune reset in autoimmune diseases.

Novartis AG (CH:NOVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CH:NOVN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 28, 2025	2025 (Q3)	1.81 / -	1.66	―	―	―
Jul 17, 2025	2025 (Q2)	1.89 / 1.95	1.588	22.84% (+0.36)	―	―
Apr 29, 2025	2025 (Q1)	1.70 / 1.84	1.451	26.67% (+0.39)	―	―
Jan 31, 2025	2024 (Q4)	1.45 / 1.60	1.233	29.41% (+0.36)	―	―
Oct 29, 2024	2024 (Q3)	1.56 / 1.66	1.402	18.39% (+0.26)	―	―
Jul 18, 2024	2024 (Q2)	1.49 / 1.59	1.398	13.61% (+0.19)	―	―
Apr 23, 2024	2024 (Q1)	1.35 / 1.45	1.306	11.04% (+0.14)	―	―
Jan 31, 2024	2023 (Q4)	1.33 / 1.23	1.161	6.18% (+0.07)	―	―
Oct 24, 2023	2023 (Q3)	1.34 / 1.40	1.207	16.15% (+0.20)	―	―
Jul 18, 2023	2023 (Q2)	1.32 / 1.40	1.192	17.24% (+0.21)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CH:NOVN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	CHF95.12	CHF93.34	-1.87%
Apr 29, 2025	CHF93.40	CHF94.21	+0.87%
Jan 31, 2025	CHF90.56	CHF92.28	+1.90%
Oct 29, 2024	CHF96.36	CHF92.43	-4.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Novartis AG (CH:NOVN) report earnings?

Novartis AG (CH:NOVN) is schdueled to report earning on Oct 28, 2025, TBA (Confirmed).

What is Novartis AG (CH:NOVN) earnings time?

Novartis AG (CH:NOVN) earnings time is at Oct 28, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Novartis AG stock?

The P/E ratio of Novartis AG is N/A.

What is CH:NOVN EPS forecast?

CH:NOVN EPS forecast for the fiscal quarter 2025 (Q3) is 1.81.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing